Quentis Therapeutics Announces the Appointment of Jeanne Magram, Ph.D. as Chief Scientific Officer Quentis Therapeutics Announces the Appointment of Jeanne Magram, Ph.D. as Chief Scientific Officer
Quentis Therapeutics Inc., a biotechnology company pursuing first-in-class endoplasmic reticulum (ER) stress response-targeted therapies to address serious diseases such as cancer,... Quentis Therapeutics Announces the Appointment of Jeanne Magram, Ph.D. as Chief Scientific Officer

Quentis Therapeutics Inc., a biotechnology company pursuing first-in-class endoplasmic reticulum (ER) stress response-targeted therapies to address serious diseases such as cancer, announced the appointment of Jeanne Magram, Ph.D. as Chief Scientific Officer. New York City-based Quentis launched in February 2017 with the completion of a $48 million Series A financing which was co-led by founding investor Versant Ventures and Polaris Partners and the affiliated LS Polaris Innovation Fund. The company is utilizing the proceeds to advance its lead immuno-oncology program, a small molecule IRE1α inhibitor, into the clinic in 2019, develop a pipeline of preclinical programs, and expand its team with key hires, such as industry veteran Magram.

“Jeanne is a welcome addition to Quentis given her experience and accomplishments across multiple therapeutic areas and modalities,” said Michael Aberman, M.D., president and CEO of Quentis Therapeutics. “This hire is an important step toward building a world-class team devoted to better understanding the role of the ER stress response in various diseases in order to discover and develop new medicines to help patients in need. This is also a homecoming for Jeanne as she rejoins the growing New York biotech ecosystem.”

Dr. Magram brings over 20 years of drug discovery and development experience to Quentis. Prior to joining Quentis, Dr. Magram was the founding Chief Scientific Officer of Northern Biologics, a Toronto Canada based biotechnology company. Prior to Northern Biologics, she served as the Site Head for Pfizer’s Centers for Therapeutic Innovation (CTI), New York, a model partnership between Pfizer and academic medical centers designed to accelerate the translation of innovative discoveries into differentiated new medicines to treat diseases of pressing unmet medical need. Previously, Dr. Magram was Vice President, Immunology & Inflammation Research at Boehringer Ingelheim, overseeing a department committed to drug discovery to address unmet medical needs in autoimmune disease. In this role, she delivered several candidates into clinical testing. Prior to Boehringer Ingelheim, Dr. Magram was an Associate Director of G Protein-Coupled Receptor (GPCR) Drug Discovery at OSI Pharmaceuticals after OSI’s acquisition of Cadus Pharmaceuticals’ Drug Discovery programs. She also previously spent over five years at Hoffmann-La Roche focused on using model systems to understand the pathophysiology of disease and to identify new therapies.

Dr. Magram completed her postdoctoral training in the laboratory of Nobel Laureate J. Michael Bishop, M.D. at the University of California, San Francisco School of Medicine and obtained her Ph.D. in the laboratory of Franklin Costantini, Ph.D. in the Department of Genetics and Development at Columbia University Irving Medical Center.

“I am excited to join Michael and the Quentis team, particularly at this time of growth and scale-up for the company,” said Dr. Magram. “With its focus on ER stress response-related drug discovery and development, Quentis is pioneering truly cutting-edge science and biology. I was attracted by the opportunity to join Quentis at this still-early stage of the company and build on its strong scientific foundation while guiding its future scientific direction as we explore applications in immuno-oncology and beyond.”

No comments so far.

Be first to leave comment below.

Your email address will not be published. Required fields are marked *

analytics.js